Bristol-Myers Squibb and Moffitt Cancer Center have entered into a collaboration agreement as part of BMS’ Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.   BMS and Moffitt will conduct a range of early phase clinic...